Results 261 to 270 of about 598,741 (306)

EGFR and anti-EGFR nanobodies: review and update

Journal of Drug Targeting, 2020
Targeted therapy is one of the favourable methods used in cancer treatment. Several recombinant proteins and small-molecules used for this aim include monoclonal antibodies, antibody fragments and peptides. Nanobody (Nb) is a camelid antibody fragment that is very effective in targeted therapy.
Jafar Sharifi, Mohammad Reza Khirehgesh, Fatemeh Safari, Bahman Akbari   +3 more
openaire   +2 more sources

EGFR-targeted therapy

Experimental Cell Research, 2011
Anti-Epidermal Growth Factor Receptor (EGFR) therapies have been recently developed for the treatment of multiple cancer types. At the time when they were introduced in clinical practice, there was little knowledge of the molecular bases of tumor sensitivity and resistance to these novel targeted compounds.
Vecchione L, Jacobs B, Normanno N, CIARDIELLO, Fortunato, Tejpar S.   +4 more
openaire   +3 more sources

Understanding eGFR

Independent Nurse, 2007
A four part presentation covering the significance of estimated glomerular filtration rate and how to use the test to diagnose chronic kidney disease
Donal O'Donoghue, Ian Wilkinson
openaire   +1 more source

EGFR blockade activates interferon

Nature Cancer, 2020
Dysregulation of innate immune signaling in cancer can be pro-tumorigenic and can promote adaptive resistance to targeted therapies. Type I interferon signaling is now shown to promote survival following inhibition of the kinase EGFR, even in cells that are not ‘addicted’ to EGFR signaling.
Ryohei Yoshida, David A. Barbie
openaire   +2 more sources

EGFR mutations and EGFR tyrosine kinase inhibitors

The Lancet Oncology, 2015
Valter, Torri, Massimo, Broggini, Marina Chiara, Garassino   +2 more
openaire   +2 more sources